WO1999003477A1 - Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide - Google Patents
Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide Download PDFInfo
- Publication number
- WO1999003477A1 WO1999003477A1 PCT/GB1998/002110 GB9802110W WO9903477A1 WO 1999003477 A1 WO1999003477 A1 WO 1999003477A1 GB 9802110 W GB9802110 W GB 9802110W WO 9903477 A1 WO9903477 A1 WO 9903477A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- insulin
- administration
- pharmaceutically acceptable
- thiazolidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Definitions
- This invention relates to a method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non- insulin dependent diabetes (NIDDM) (or Type 2 diabetes) and conditions associated with diabetes mellitus.
- NIDDM non- insulin dependent diabetes
- Insulin secretagogues are compounds which promote increased secretion of insulin by the pancreatic beta cells.
- the sulphonylureas are well known examples of insulin secretagogues.
- the sulphonylureas act as antihyperglycaemic agents and are used in the treatment of Type 2 diabetes).
- Examples of sulphonylureas include glibenclamide, glipizide, gliclazide, glimepiride. tolazamide and tolbutamide.
- Biguanide antihyperglycaemic agents are commonly used in the treatment of Type 2 diabetes).
- 1,1 - Dimethylbiguanidine (or Metformin) is an example of a biguanide antihyperglycaemic agent.
- European Patent Application, Publication Number 0,306.228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and antihyperlipidaemic activity.
- One particular thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4- dione (hereinafter 'Compound (I)').
- WO94/05659 discloses certain salts of Compound (I) including the maleate salt.
- Compound (I) is an example of a class of anti-hyperglycaemic agents known as 'insulin sensitisers'.
- Compound (I) is a thiazolidinedione insulin sensitiser.
- Another series of compounds generally recognised as having insulin sensitiser activity are those typified by the compounds disclosed in International Patent Applications, Publication Numbers WO93/21 166 and WO94/01420. These compounds are herein referred to as 'acyclic insulin sensitisers'. Other examples of acyclic insulin sensitisers are those disclosed in United States Patent Number 5232945 and International Patent Applications, Publication Numbers WO92/03425 and WO91/19702.
- the invention provides a method for the treatment of diabetes mellitus, especially Type 2 diabetes, and conditions associated with diabetes mellitus, in a marnmal such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent, to a mammal in need thereof.
- the method comprises either co-administration of the insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent or sequential administration thereof.
- Co-administration includes administration of a formulation which includes an insulin sensitiser, an insulin secretagogue and a biguanide antihyperglycaemic agent or the essentially simultaneous administration of separate formulations of each agent.
- an insulin sensitiser such as Compound (I)
- an insulin secretagogue and a biguanide antihyperglycaemic agent in the manufacture of a composition for the treatment of diabetes mellitus, especially Type 2 diabetes and conditions associated with diabetes mellitus.
- a suitable insulin sensitiser is a thiazolidinedione insulin sensitiser.
- a suitable thiazolidinedione insulin sensitiser is Compound (I).
- Other suitable thiazolidinedione insulin sensitisers include (+) -5-[[4-[(3,4- dihydro-6-hydroxy-2, 5, 7, 8-tetramethyl-2H-l-benzopyran-2- yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(l- methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5- ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2- benzyl-2,3-dihydrobenzopyr
- sulphonylureas include acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glyclopyamide and glycylamide.
- suitable insulin secretagogues include repaglinide.
- a suitable biguanide antihyperglycaemic agent is metformin. buformin or phenformin, especially metformin.
- the method comprises the administration of 2 to 12 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 2 to 4. 4 to 8 or 8 to
- the method comprises the administration of 2 to 4mg of Compound (I), especially when administered per day.
- the method comprises the administration of 4 to 8mg of Compound (I), especially when administered per day.
- the method comprises the administration of 8 to 12 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 2 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 4 mg of Compound
- the method comprises the administration of 8 mg of Compound (I), especially when administered per day.
- the insulin sensitiser such as compound (I)
- the insulin secretagogue and the biguanide antihyperglycaemic agent are each administered in a pharmaceutically acceptable form, including pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate.
- pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof.
- the names used for the relevant insulin secretagogues and the biguanide antihyperglycaemic agents may relate to a particular pharmaceutical form of the relevant active agent: It will be understood that all pharmaceutically acceptable forms of the active agents per se are encompassed by this invention.
- Suitable pharmaceutically acceptable salted forms of the insulin sensitisers include those described in the above mentioned patents and patent applications such as in EP 0306228 and WO94/05659 for Compound (I).
- a preferred pharmaceutically acceptable salt for Compound (I) is a maleate.
- Suitable pharmaceutically acceptable solvated forms of the insulin sensitisers include those described in the above mentioned patents and patent applications, such as in EP 0306228 and WO94/05659 for Compound (I), in particular hydrates.
- Suitable pharmaceutically acceptable forms of the insulin secretagogue and the biguanide antihyperglycaemic agent depend upon the particular compound used but include known pharmaceutically acceptable forms of the particular compound chosen. Such derivatives are found or are referred to in standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
- the insulin sensitisers such as Compound (I) or, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, may be prepared using known methods, for example those disclosed in the above mentioned patents and patent applications, such as EP 0306228 and WO94/05659 for Compound (I).
- EP 0306228 and WO94/05659 for Compound (I).
- the disclosures of the above mentioned patents and patent applications, such as EP 0306228 and WO94/05659, are incorporated herein by reference.
- Compound (I) may exist in one of several tautomeric forms, all of which are encompassed by the term Compound (I) as individual tautomeric forms or as mixtures thereof.
- Compound (I) contains a chiral carbon atom, and hence can exist in up to two stereoisomeric forms, the term Compound (I) encompasses all of these isomeric forms whether as individual isomers or as mixtures of isomers, including racemates.
- the insulin secretagogue and biguanide antihyperglycaemic agent of choice is prepared according to known methods, such methods are found or are referred to in standard reference texts, such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31 st Edition page 341 and pages cited therein).
- 'conditions associated with diabetes' includes conditions associated with diabetes mellitus itself and complications associated with diabetes mellitus. Also included in 'conditions associated with diabetes' are those conditions associated with the pre-diabetic state.
- condition associated with the pre-diabetic state' includes conditions such as insulin resistance, including hereditary insulin resistance, impaired glucose tolerance and hyperinsulinaemia.
- 'Conditions associated with diabetes mellitus itself include hyperglycaemia, insulin resistance, including acquired insulin resistance. Further conditions associated with diabetes mellitus itself include hypertension and cardiovascular disease, especially atherosclerosis and conditions associated with insulin resistance. Conditions associated with insulin resistance include polycystic ovarian syndrome and steroid induced insulin resistance and gestational diabetes. 'Complications associated with diabetes mellitus' includes renal disease, especially renal disease associated with Type 2 diabetes, neuropathy and retinopathy.
- Renal diseases associated with Type 2 diabetes include nephropathy, glomerulonephritis, glomerular sclerosis, hypertensive nephrosclerosis and end stage
- Additional renal diseases associated with Type 2 diabetes include nephrotic syndrome.
- scalar amounts including mg amounts, of Compound (I) in a pharmaceutically acceptable form
- the scalar amount referred to is made in respect of Compound (I) per se:
- 2 mg of Compound (I) in the form of the maleate salt is that amount of maleate salt which contains 2 mg of Compound (I).
- Diabetes mellitus is preferably Type 2 diabetes.
- the particularly beneficial effect on glycaemic control provided by the treatment of the invention is indicated to be a synergistic effect relative to the control expected for the sum of the effects of the individual active agents.
- the insulin sensitiser is the agent of first administration.
- Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (HbAlc). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Sau. med. Wschr.
- the dosage level of each of the active agents when used in accordance with the treatment of the invention will be less than would have been required from a purely additive effect upon glycaemic control.
- the treatment of the invention will effect an improvement, relative to the individual agents, in the levels of advanced glycosylation end products (AGEs), leptin and serum lipids including total cholesterol, HDL- cholesterol, LDL-cholesterol including improvements in the ratios thereof, in particular an improvement in serum lipids including total cholesterol, HDL- cholesterol, LDL-cholesterol including improvements in the ratios thereof.
- AGEs advanced glycosylation end products
- leptin and serum lipids including total cholesterol, HDL- cholesterol, LDL-cholesterol including improvements in the ratios thereof, in particular an improvement in serum lipids including total cholesterol, HDL- cholesterol, LDL-cholesterol including improvements in the ratios thereof.
- the term 'pharmaceutically acceptable embraces both human and veterinary use: for example the term 'pharmaceutically acceptable' embraces a veterinarily acceptable compound.
- the active medicaments are preferably administered in pharmaceutical composition form.
- such compositions can include all medicaments or one only of the medicaments.
- the present invention also provides a pharmaceutical composition comprising an insulin sensitiser, such as Compound (I) and especially 2 to 12 mg thereof, an insulin secretagogue and a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
- Such compositions may be prepared by admixing an insulin sensitiser, such as Compound (I) and especially 2 to 12 mg thereof, an insulin secretagogue and a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
- the compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.
- compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
- composition of the invention is in the form of a unit dose.
- Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone: fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants. for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
- the compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
- Suitable dosages for the insulin sensitisers include those disclosed in the abovementioned patents and patent applications.
- Suitable dosages, including unit dosages, of Compound (I) comprise 1. 2, 3, 4, 5, 6, 7, 8. 9, 10, 11 or 12 mg of Compound (I).
- the medicaments may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
- Particular dosages of Compound (I) are 2mg/day, 4mg/day, including 2mg twice per day, and 8 mg/day, including 4mg twice per day.
- Suitable dosages including unit dosages of the insulin secretagogue. such as the sulphonylurea. or the biguanide antihyperglycaemic agent include the known dosages including unit doses for these compounds as described or referred to in reference text such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
- a typical daily dosage of glibenclamide is in the range of from 2.5 to 20 mg, for example lOmg twice per day or 20mg once per day; a typical daily dosage of glipizide is in the range of from 2.5 to 40 mg; a typical daily dosage of gliclazide is in the range of from 40 to 320 mg; a typical daily dosage of tolazamide is in the range of from 100 to 1000 mg; a typical daily dosage of tolbutamide is in the range of from 1000 to 3000 mg; a typical daily dosage of chlorpropamide is in the range of from 100 to 500 mg; and a typical daily dosage of gliquidone is in the range of from 15 to 180 mg.
- Repaglinide may be taken in amounts, usually in the range of from 0.5mg to
- suitable dosages of metformin include up to 3000mg per day, in unit doses of 500mg (for example two or three times per day) or 850mg (for example two times per day), one example of a dosage for metformin is 500mg once building to five times per day.
- the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
- the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
- Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitation with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
- suspending agents for example sorbitol, syrup, methyl cellulose
- fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the Compound (I) is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
- compositions can contain from 0.1% to 99% by weight, preferably from
- composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
- the compositions are prepared and formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, 's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) and Harry's Cosmeticology (Leonard Hill Books) (for example see the 31st Edition page 341 and pages cited therein).
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising an insulin sensitiser, such as Compound (I) and especially 2 to 12 mg thereof, an insulin secretagogue and a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance.
- the invention also provides the use of an insulin sensitiser, such as Compound (I) and especially 2 to 12 mg thereof, an insulin secretagogue and a biguanide antihyperglycaemic agent for the manufacture of a medicament for the treatment of diabetes mellitus and conditions associated with diabetes.
- an insulin sensitiser such as Compound (I) and especially 2 to 12 mg thereof, an insulin secretagogue and a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use in the treatment of diabetes mellitus and conditions associated with diabetes mellitus.
- a range of 2 to 4mg includes a range of 2.1 to 4, 2.2 to 4, 2.3 to 4, 2.4 to 4,
- a range of 4 to 8mg includes a range of 4.1 to 8, 4.2 to 8, 4.3 to 8, 4.4 to 8, 4.5 to 8, 4.6 to 8, 4.7 to 8, 4.8 to 8, 4.9 to 8, 5 to 8, 6 to 8 or 7 to 8mg.
- a range of 8 to 12 mg includes a range of 8.1 to 12, 8.2 to 12, 8.3 to 12, 8.4 to 12, 8.5 to 12, 8.6 to 12, 8.7 to 12, 8.8 to 12, 8.9 to 12, 9 to 12, 10 to 12 or 1 1 to 12mg.
- compositions or methods of the invention in the abovementioned dosage ranges.
- Microcrystalline Cellulose 20.0 (Avicel PH102)
- the concentrate was then formulated into tablets using the following:
- Microcrystalline Cellulose (Avicel PHI 02) 27.85 25.85 21.85 43.70
- Lactose monohydrate (Pharmatose DCL15), 104.44 96.94 81.94 163.88
- compositions for other active agents are as described in the above mentioned publications.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU84488/98A AU8448898A (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
BR9810445-4A BR9810445A (en) | 1997-07-18 | 1998-07-16 | Diabetes treatment with thiazolidinedione, insulin secretagogue and diguanide |
EP98935127A EP1001783B1 (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
SK59-2000A SK285484B6 (en) | 1997-07-18 | 1998-07-16 | Combination comprising 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, insulin secretagogue and biguanide antihyperglycaemic agent, pharmaceutical composition comprising this combination and its use for treatment of diabetes |
KR1020007000512A KR100671918B1 (en) | 1997-07-18 | 1998-07-16 | Treatment of Diabetes with Thiazolidinedione, Insulin Secretagogue and Diguanide |
NZ501164A NZ501164A (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with a thiazolidinedione, an insulin secretagogue and a biguanide |
APAP/P/2000/001733A AP1352A (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide. |
EA200000139A EA003021B1 (en) | 1997-07-18 | 1998-07-16 | Use of insulin sensitiser, an insulin secretagogue and a biguanide antyhyperglycaemic agent for treating diabetes mellitius |
PL378474A PL198017B1 (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
PL338126A PL197844B1 (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes by means of derivatives of thiazolydinone, of insulin secretion stimulating agent and of biguanidinic derivative |
HU0003629A HUP0003629A3 (en) | 1997-07-18 | 1998-07-16 | Synergic pharmaceutical composition for the treatment of diabetes containing thiazolidinedione, insulin secretagogue and diguanide |
SI9830804T SI1001783T1 (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
IL13404698A IL134046A0 (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
JP2000502776A JP2001510159A (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
AT98935127T ATE305790T1 (en) | 1997-07-18 | 1998-07-16 | TREATMENT OF DIABETES WITH THIAZOLIDINDIONE, INSULIN SECRETION PROMOTERS AND BIGUANIDE |
UA2000010261A UA70303C2 (en) | 1997-07-18 | 1998-07-16 | Method for treatment of diabetes mellitus with thiazolidinedion, insulin secretagogue, and biguanide |
DE69831808T DE69831808T2 (en) | 1997-07-18 | 1998-07-16 | TREATMENT OF DIABETES WITH THIAZOLIDE INDIONES, INSULIN SEKRETION PROMOTERS AND BIG UANIDE |
CA002296653A CA2296653C (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and biguanide |
NO20000228A NO325727B1 (en) | 1997-07-18 | 2000-01-17 | Combination of an insulin sensitizer and insulin secretion for the treatment of diabetes. |
HK00107103A HK1028550A1 (en) | 1997-07-18 | 2000-11-08 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
CY20051101486T CY1105254T1 (en) | 1997-07-18 | 2005-12-07 | TREATMENT OF DIABETES WITH A THIAZOLIDINEDIONE, AN INSULIN SECRETAGO AND DIGUANIDIUM |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9715295A GB9715295D0 (en) | 1997-07-18 | 1997-07-18 | Novel method of treatment |
GB9715295.3 | 1997-07-18 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09446039 A-371-Of-International | 1999-12-15 | ||
US44603999A A-371-Of-International | 1997-07-18 | 1999-12-15 | |
US09/939,470 Continuation US20020016287A1 (en) | 1997-07-18 | 2001-08-24 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999003477A1 true WO1999003477A1 (en) | 1999-01-28 |
Family
ID=10816167
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1998/002110 WO1999003477A1 (en) | 1997-07-18 | 1998-07-16 | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
Country Status (40)
Country | Link |
---|---|
EP (1) | EP1001783B1 (en) |
JP (2) | JP2001510159A (en) |
KR (1) | KR100671918B1 (en) |
CN (1) | CN1264303A (en) |
AP (1) | AP1352A (en) |
AR (1) | AR016349A1 (en) |
AT (1) | ATE305790T1 (en) |
AU (1) | AU8448898A (en) |
BG (1) | BG64785B1 (en) |
BR (1) | BR9810445A (en) |
CA (1) | CA2296653C (en) |
CO (1) | CO4940420A1 (en) |
CY (1) | CY1105254T1 (en) |
DE (1) | DE69831808T2 (en) |
DK (1) | DK1001783T3 (en) |
DZ (1) | DZ2562A1 (en) |
EA (1) | EA003021B1 (en) |
ES (1) | ES2251093T3 (en) |
GB (1) | GB9715295D0 (en) |
HK (1) | HK1028550A1 (en) |
HU (1) | HUP0003629A3 (en) |
ID (1) | ID24211A (en) |
IL (1) | IL134046A0 (en) |
IN (1) | IN189275B (en) |
MA (1) | MA24607A1 (en) |
MY (1) | MY155219A (en) |
NO (1) | NO325727B1 (en) |
NZ (2) | NZ501164A (en) |
OA (1) | OA11279A (en) |
PE (1) | PE99599A1 (en) |
PL (2) | PL198017B1 (en) |
SA (1) | SA98190468B1 (en) |
SI (1) | SI1001783T1 (en) |
SK (1) | SK285484B6 (en) |
TR (1) | TR200000134T2 (en) |
TW (1) | TW505516B (en) |
UA (1) | UA70303C2 (en) |
UY (1) | UY25102A1 (en) |
WO (1) | WO1999003477A1 (en) |
ZA (1) | ZA986363B (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027401A1 (en) * | 1998-11-09 | 2000-05-18 | Warner-Lambert Company | Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide |
WO2000028989A1 (en) * | 1998-11-12 | 2000-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
WO2001013121A1 (en) * | 1999-08-13 | 2001-02-22 | Biovitrum Ab | Methods for identification of compounds stimulating insulin secretion |
WO2001035941A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Novel composition based on a thiazolidinedione and metformin and use |
WO2001035940A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
FR2812547A1 (en) * | 2000-08-04 | 2002-02-08 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING A METFORMIN AND THIAZOLIDINEDIONION DERIVATIVE AND ITS USE FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES |
WO2003006004A2 (en) * | 2001-07-09 | 2003-01-23 | L. Molteni & C. Dei Fratelli Alitti - Societa' Di Esercizio S.P.A. | Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide, a sulphonyl urea |
EP1429747A1 (en) * | 2001-07-10 | 2004-06-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
EP1738751A2 (en) | 2001-01-12 | 2007-01-03 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
WO2007043853A1 (en) * | 2005-10-12 | 2007-04-19 | World-Trade Import-Export, Wtie, Ag. | Pharmaceutical compositions comprising combined antidiabetic substances for use in diabetes mellitus |
WO2008050987A1 (en) * | 2006-10-23 | 2008-05-02 | Hanall Pharmaceutical Co., Ltd. | Combination formulation with controlled release comprising metformin and glimepiride |
US7700128B2 (en) | 2003-10-31 | 2010-04-20 | Takeda Pharmaceutical Company Limited | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
US9101660B2 (en) | 2002-10-07 | 2015-08-11 | Takeda Pharmaceutical Company | Solid preparation |
EP3698801A4 (en) * | 2017-10-20 | 2021-07-21 | Novmetapharma Co., Ltd. | Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101417130B (en) * | 2007-10-22 | 2010-10-06 | 鲁南制药集团股份有限公司 | Medicine combination for treating II type diabetes and complicating diseases thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003724A1 (en) * | 1991-08-26 | 1993-03-04 | The Upjohn Company | Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride |
WO1996009823A1 (en) * | 1994-09-28 | 1996-04-04 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
EP0749751A2 (en) * | 1995-06-20 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for use in tteatment of diabetes |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS6051189A (en) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | Thiazolidine derivative and its preparation |
US4582839A (en) * | 1984-03-21 | 1986-04-15 | Takeda Chemical Industries, Ltd. | 2,4-thiazolidinediones |
CN1003445B (en) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | The preparation method of thiazolidine diketone derivative |
JPH06779B2 (en) * | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | Thiazolidione derivative and pharmaceutical composition comprising the same |
US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
US4791125A (en) * | 1987-12-02 | 1988-12-13 | Pfizer Inc. | Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents |
US5061717A (en) * | 1988-03-08 | 1991-10-29 | Pfizer Inc. | Thiazolidinedione hypoglycemic agents |
WO1989008651A1 (en) * | 1988-03-08 | 1989-09-21 | Pfizer Inc. | Hypoglycemic thiazolidinedione derivatives |
WO1991007107A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
JPH04210683A (en) * | 1990-12-06 | 1992-07-31 | Terumo Corp | Thiazolidine-2,4-dione derivative and treating agent for diabetic complication containing the same derivative |
EA003025B1 (en) * | 1997-06-18 | 2002-12-26 | Смитклайн Бичам Плс | Treatment of diabetes with thiazolidinedione and sulphonylures |
-
1997
- 1997-07-18 GB GB9715295A patent/GB9715295D0/en active Pending
-
1998
- 1998-07-15 DZ DZ980172A patent/DZ2562A1/en active
- 1998-07-16 PL PL378474A patent/PL198017B1/en not_active IP Right Cessation
- 1998-07-16 EP EP98935127A patent/EP1001783B1/en not_active Expired - Lifetime
- 1998-07-16 AU AU84488/98A patent/AU8448898A/en not_active Abandoned
- 1998-07-16 UA UA2000010261A patent/UA70303C2/en unknown
- 1998-07-16 SK SK59-2000A patent/SK285484B6/en not_active IP Right Cessation
- 1998-07-16 HU HU0003629A patent/HUP0003629A3/en unknown
- 1998-07-16 PL PL338126A patent/PL197844B1/en not_active IP Right Cessation
- 1998-07-16 CA CA002296653A patent/CA2296653C/en not_active Expired - Fee Related
- 1998-07-16 ES ES98935127T patent/ES2251093T3/en not_active Expired - Lifetime
- 1998-07-16 NZ NZ501164A patent/NZ501164A/en unknown
- 1998-07-16 SI SI9830804T patent/SI1001783T1/en unknown
- 1998-07-16 EA EA200000139A patent/EA003021B1/en not_active IP Right Cessation
- 1998-07-16 BR BR9810445-4A patent/BR9810445A/en not_active Application Discontinuation
- 1998-07-16 TR TR2000/00134T patent/TR200000134T2/en unknown
- 1998-07-16 PE PE1998000629A patent/PE99599A1/en not_active Application Discontinuation
- 1998-07-16 JP JP2000502776A patent/JP2001510159A/en not_active Withdrawn
- 1998-07-16 CN CN98807319A patent/CN1264303A/en active Pending
- 1998-07-16 ID IDW20000075A patent/ID24211A/en unknown
- 1998-07-16 MA MA25171A patent/MA24607A1/en unknown
- 1998-07-16 WO PCT/GB1998/002110 patent/WO1999003477A1/en active IP Right Grant
- 1998-07-16 AP APAP/P/2000/001733A patent/AP1352A/en active
- 1998-07-16 AR ARP980103481A patent/AR016349A1/en unknown
- 1998-07-16 DE DE69831808T patent/DE69831808T2/en not_active Expired - Fee Related
- 1998-07-16 AT AT98935127T patent/ATE305790T1/en not_active IP Right Cessation
- 1998-07-16 NZ NZ511608A patent/NZ511608A/en unknown
- 1998-07-16 KR KR1020007000512A patent/KR100671918B1/en not_active IP Right Cessation
- 1998-07-16 DK DK98935127T patent/DK1001783T3/en active
- 1998-07-16 IL IL13404698A patent/IL134046A0/en unknown
- 1998-07-17 ZA ZA9806363A patent/ZA986363B/en unknown
- 1998-07-17 TW TW087111770A patent/TW505516B/en active
- 1998-07-17 UY UY25102A patent/UY25102A1/en not_active IP Right Cessation
- 1998-07-17 CO CO98040747A patent/CO4940420A1/en unknown
- 1998-07-17 MY MYPI98003288A patent/MY155219A/en unknown
- 1998-07-20 IN IN2087DE1998 patent/IN189275B/en unknown
- 1998-08-29 SA SA98190468A patent/SA98190468B1/en unknown
-
2000
- 2000-01-17 NO NO20000228A patent/NO325727B1/en not_active IP Right Cessation
- 2000-01-18 OA OA1200000012A patent/OA11279A/en unknown
- 2000-02-07 BG BG104135A patent/BG64785B1/en unknown
- 2000-11-08 HK HK00107103A patent/HK1028550A1/en not_active IP Right Cessation
-
2005
- 2005-04-21 JP JP2005123562A patent/JP2005213273A/en active Pending
- 2005-12-07 CY CY20051101486T patent/CY1105254T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003724A1 (en) * | 1991-08-26 | 1993-03-04 | The Upjohn Company | Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone glibenclamide or glimepiride |
WO1996009823A1 (en) * | 1994-09-28 | 1996-04-04 | Shaman Pharmaceuticals, Inc. | Hypoglycemic agent from cryptolepis |
EP0749751A2 (en) * | 1995-06-20 | 1996-12-27 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for use in tteatment of diabetes |
Non-Patent Citations (4)
Title |
---|
ELSON DF ET AL: "Therapy for type 2 diabetes mellitus [see comments]", WMJ, MAR 1998, 97 (3) P49-54, UNITED STATES, XP002081122 * |
KAPPEL C. ET AL: "Type 2 diabetes: Update on therapy", COMPREHENSIVE THERAPY, vol. 24, no. 6-7, June 1998 (1998-06-01), pages 319 - 326, XP002080974 * |
SCHEEN AJ ET AL: "Oral antidiabetic agents. A guide to selection.", DRUGS, FEB 1998, 55 (2) P225-36, NEW ZEALAND, XP002080821 * |
WOLFFENBUTTEL B. ET AL: "New treatments for patients with type 2 diabetes mellitus", POSTGRAD MED, vol. 72, pages 657 - 662, XP002081123 * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6099862A (en) * | 1998-08-31 | 2000-08-08 | Andrx Corporation | Oral dosage form for the controlled release of a biguanide and sulfonylurea |
EP1514550A3 (en) * | 1998-11-09 | 2009-04-29 | Warner-Lambert Company LLC | Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide |
WO2000027401A1 (en) * | 1998-11-09 | 2000-05-18 | Warner-Lambert Company | Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide |
EP1514550A2 (en) * | 1998-11-09 | 2005-03-16 | Warner-Lambert Company Llc | Combinations for diabetes which contain a sulfonylurea, a glitazone and a biguanide |
EP1992337A1 (en) * | 1998-11-12 | 2008-11-19 | Smithkline Beecham Plc | Novel modified release composition and use |
WO2000028989A1 (en) * | 1998-11-12 | 2000-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
EP1813273A1 (en) * | 1998-11-12 | 2007-08-01 | Smithkline Beecham Plc | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
EA007610B1 (en) * | 1998-11-12 | 2006-12-29 | Смитклайн Бичам Плс | Enteric coated tablet providing sustained release |
HRP20010343B1 (en) * | 1998-11-12 | 2010-11-30 | Smithkline Beecham P.L.C. | Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
WO2001013121A1 (en) * | 1999-08-13 | 2001-02-22 | Biovitrum Ab | Methods for identification of compounds stimulating insulin secretion |
HRP20020416B1 (en) * | 1999-11-16 | 2011-04-30 | Smithkline Beecham P.L.C. | Novel composition and use |
WO2001035941A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Novel composition based on a thiazolidinedione and metformin and use |
US8236345B2 (en) | 1999-11-16 | 2012-08-07 | Smithkline Beecham Limited | Composition and use |
WO2001035941A3 (en) * | 1999-11-16 | 2002-05-23 | Smithkline Beecham Plc | Novel composition based on a thiazolidinedione and metformin and use |
WO2001035940A3 (en) * | 1999-11-16 | 2002-03-21 | Smithkline Beecham Plc | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
EP1520581A1 (en) * | 1999-11-16 | 2005-04-06 | Smithkline Beecham Plc | Composition based on a thiazolidinedione and metformin and its use |
AP1389A (en) * | 1999-11-16 | 2005-04-14 | Smithkline Beecham Plc | Pharmaceutical composition of thiazolidinedione and metformin hydrochloride, useful in the treatment of diabetes mellitus. |
EP1913945A3 (en) * | 1999-11-16 | 2008-04-30 | Smithkline Beecham Plc | Composition based on a thiazolidinedione and metformin and its use |
EP1913945A2 (en) * | 1999-11-16 | 2008-04-23 | Smithkline Beecham Plc | Composition based on a thiazolidinedione and metformin and its use |
WO2001035940A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
CZ302500B6 (en) * | 1999-11-16 | 2011-06-22 | Smithkline Beecham P. L. C. | Pharmaceutical composition containing thiazolidinedione, metformin hydrochloride and pharmaceutically acceptable carrier, and use thereof |
KR100760063B1 (en) * | 1999-11-16 | 2007-09-18 | 스미스클라인비이참피이엘시이 | Novel Composition and Use |
FR2812547A1 (en) * | 2000-08-04 | 2002-02-08 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING A METFORMIN AND THIAZOLIDINEDIONION DERIVATIVE AND ITS USE FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES |
WO2002011721A1 (en) * | 2000-08-04 | 2002-02-14 | Merck Patent Gmbh | Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative |
EP1738751A2 (en) | 2001-01-12 | 2007-01-03 | Sun Pharmaceutical Industries Limited | Spaced drug delivery system |
US7964216B2 (en) | 2001-01-12 | 2011-06-21 | Sun Pharma Advanced Research Company Limited | Spaced drug delivery system |
WO2003006004A3 (en) * | 2001-07-09 | 2003-04-17 | Molteni & C | Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide, a sulphonyl urea |
WO2003006004A2 (en) * | 2001-07-09 | 2003-01-23 | L. Molteni & C. Dei Fratelli Alitti - Societa' Di Esercizio S.P.A. | Pharmaceutical compositions for oral use, containing, in combination, metformin and glicazide, a sulphonyl urea |
EP1429747A4 (en) * | 2001-07-10 | 2005-01-05 | Kos Life Sciences Inc | Core formulation comprising pioglitazone hydrochloride and a biguanide |
EP1429747A1 (en) * | 2001-07-10 | 2004-06-23 | Kos Life Sciences, Inc. | Core formulation comprising pioglitazone hydrochloride and a biguanide |
US8911781B2 (en) | 2002-06-17 | 2014-12-16 | Inventia Healthcare Private Limited | Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides |
US9101660B2 (en) | 2002-10-07 | 2015-08-11 | Takeda Pharmaceutical Company | Solid preparation |
US7700128B2 (en) | 2003-10-31 | 2010-04-20 | Takeda Pharmaceutical Company Limited | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester |
WO2007043853A1 (en) * | 2005-10-12 | 2007-04-19 | World-Trade Import-Export, Wtie, Ag. | Pharmaceutical compositions comprising combined antidiabetic substances for use in diabetes mellitus |
WO2008050987A1 (en) * | 2006-10-23 | 2008-05-02 | Hanall Pharmaceutical Co., Ltd. | Combination formulation with controlled release comprising metformin and glimepiride |
EP3698801A4 (en) * | 2017-10-20 | 2021-07-21 | Novmetapharma Co., Ltd. | Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients |
US11607441B2 (en) | 2017-10-20 | 2023-03-21 | Novmetapharma Co., Ltd. | Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070004780A1 (en) | Treatment of Diabetes with Thiazolidinedione and Metformin | |
US20030109553A1 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
EP1001783B1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
US20080058388A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
EP1001784A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor | |
US20020016287A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
EP0999845A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
WO1999003476A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
WO1998057635A1 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor | |
US20030109561A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
US20020052324A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
US20020123514A1 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor | |
AU2928002A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
AU2005227371A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
MXPA00000633A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
MXPA00000655A (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
CA2549864A1 (en) | Treatment of diabetes with thiazolidinedione and metformin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 134046 Country of ref document: IL Ref document number: 1200000036 Country of ref document: VN Ref document number: 98807319.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 501164 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998935127 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 84488/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09446039 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 592000 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007000512 Country of ref document: KR Ref document number: PV2000-172 Country of ref document: CZ Ref document number: PA/a/2000/000633 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2296653 Country of ref document: CA Ref document number: 2296653 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/00134 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000139 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998935127 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000512 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-172 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998935127 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007000512 Country of ref document: KR |